U.S. markets close in 1 hour 21 minutes
  • S&P 500

    3,827.84
    +59.37 (+1.58%)
     
  • Dow 30

    31,369.85
    +445.71 (+1.44%)
     
  • Nasdaq

    12,871.03
    +147.56 (+1.16%)
     
  • Russell 2000

    2,159.47
    +12.54 (+0.58%)
     
  • Crude Oil

    66.12
    +2.29 (+3.59%)
     
  • Gold

    1,695.80
    -4.90 (-0.29%)
     
  • Silver

    25.22
    -0.25 (-0.97%)
     
  • EUR/USD

    1.1919
    -0.0060 (-0.50%)
     
  • 10-Yr Bond

    1.5520
    +0.0020 (+0.13%)
     
  • GBP/USD

    1.3839
    -0.0055 (-0.39%)
     
  • USD/JPY

    108.3290
    +0.3530 (+0.33%)
     
  • BTC-USD

    48,934.79
    +495.62 (+1.02%)
     
  • CMC Crypto 200

    977.86
    +34.69 (+3.68%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.79 (-0.23%)
     

Altimmune To Announce Year End 2020 Financial Results on February 25, 2021

  • Oops!
    Something went wrong.
    Please try again later.
Altimmune, Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results on Thursday, February 25th, 2021.

Altimmune management will host a conference call for investors beginning at 8:30 am ET on Thursday, February 25th, 2021 to discuss financial results and provide a business update.

Conference Call Information:

Date:

Thursday, February 25, 2021

Time:

8:30 am Eastern Time

Domestic Dial-in:

877-423-9813

International Dial-in:

201-689-8573

Conference ID:

13716171

Webcast:

http://public.viavid.com/index.php?id=143423

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

Investor & Media Contacts:

Will Brown

Stacey Jurchison

Chief Financial Officer

Sr. Dir, Investor Relations

Phone: 240-654-1450

Phone : 410-474-8200

wbrown@altimmune.com

sjurchison@altimmune.com